Magenta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm one of the biotech analysts at JP Morgan. And we're continuing the 2020 Healthcare Conference this morning with Magenta. We're going to host a Q&A session with the management team right after this. It's just down the hall in the Yorkshire room, that way. But for the presentation, I'm going to turn it over to the company's CEO, Jason Gardner.
Good morning. Thank you, Jess, and thank you to the JP Morgan team for inviting Magenta to present. I'm Jason Gardner, CEO. It's an honor to share our company progress today, last year, what we did, what we accomplished and executed and our forward plans in 2020 and the big vision to reset patients across many -- immune systems across many different diseases. I'd also like to thank the Magentini, our teams back in Cambridge, and everybody else who is also dialed in and spending time with us on the webcast
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |